Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report)’s share price reached a new 52-week high on Thursday . The company traded as high as $26.50 and last traded at $26.50, with a volume of 881 shares changing hands. The stock had previously closed at $24.59.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada upgraded shares of Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Tuesday, December 10th.
View Our Latest Stock Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Up 0.5 %
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Bloom Energy: Powering the Future With Decentralized Energy
- Investing In Automotive Stocks
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Why Invest in 5G? How to Invest in 5G Stocks
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
